Literature DB >> 11523216

Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma.

Z Peng1, H Tang, Y Ling, G Han.   

Abstract

To investigate the roles of apoptosis and the Fas system (Fas, Fas ligand, soluble Fas) in the process of liver cirrhosis (LC) converting into hepatocellular carcinoma (HCC), expression of Fas and Fas ligand (FasL) in 49 LC and 36 HCC samples was detected by immunohistochemical method. Apoptosis was detected by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) method. Serum soluble Fas (sFas) levels in 28 cases of LC and 27 cases of HCC were measured by enzyme-linked immunosorbent assay (ELISA) method. Compared with LC, apoptotic indices (AI) in HCC tissues were significantly reduced (P < 0.001), expression of Fas was decreased (P < 0.05), and that of FasL was increased (P < 0.05). Serum sFas levels in HCC patients were significantly higher than those in normal controls. Down-regulation of Fas expression, up-regulation of FasL expression in hepatocytes and elevation of sFas level in serum might contribute to tumor escape from immune surveillance of the body. Apoptosis and the Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523216     DOI: 10.1007/BF02888075

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  14 in total

Review 1.  Programmed cell death: apoptosis and oncogenesis.

Authors:  G T Williams
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

2.  Fas antigen expression in hepatocellular carcinoma tissues.

Authors:  Y Ito; T Takeda; K Umeshita; M Sakon; K Wakasa; N Matsuura; M Monden
Journal:  Oncol Rep       Date:  1998 Jan-Feb       Impact factor: 3.906

3.  Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines.

Authors:  H Yano; K Fukuda; M Haramaki; S Momosaki; S Ogasawara; K Higaki; M Kojiro
Journal:  J Hepatol       Date:  1996-10       Impact factor: 25.083

4.  Fas system and apoptosis in viral hepatitis.

Authors:  N Hayashi; E Mita
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

5.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

Authors:  G Papoff; I Cascino; A Eramo; G Starace; D H Lynch; G Ruberti
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

6.  Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver.

Authors:  B Grasl-Kraupp; W Bursch; B Ruttkay-Nedecky; A Wagner; B Lauer; R Schulte-Hermann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

Authors:  S Jodo; S Kobayashi; Y Nakajima; T Matsunaga; N Nakayama; N Ogura; N Kayagaki; K Okumura; T Koike
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 8.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

9.  A quantitative evaluation of apoptotic bodies in rat liver.

Authors:  A Benedetti; A M Jezequel; F Orlandi
Journal:  Liver       Date:  1988-06

10.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Authors:  P R Galle; W J Hofmann; H Walczak; H Schaller; G Otto; W Stremmel; P H Krammer; L Runkel
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  2 in total

1.  The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma.

Authors:  Olfat Hammam; Ola Mahmoud; Manal Zahran; Sohair Aly; Karim Hosny; Amira Helmy; Amgad Anas
Journal:  Hepat Mon       Date:  2012-11-03       Impact factor: 0.660

2.  Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer.

Authors:  Adriana Aguilar-Lemarroy; Jose E Romero-Ramos; Vicente Olimon-Andalon; Georgina Hernandez-Flores; Jose M Lerma-Diaz; Pablo C Ortiz-Lazareno; Gilberto Morgan-Villela; Susana Del Toro-Arreola; Alejandro Bravo-Cuellar; Luis F Jave-Suarez
Journal:  BMC Cancer       Date:  2008-04-11       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.